LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Generated: 2026-11-18
Case ID: NM_000059.4_c.598A_G_20261118_200121
Framework: ACMG/AMP 2015 with ENIGMA Table 3 adaptations
Variant classification summary

NM_000059.4:c.598A>G

BRCA2  · NP_000050.3:p.(Thr200Ala)  · NM_000059.4
GRCh37: chr13:32900717 A>G  ·  GRCh38: chr13:32326580 A>G
Gene: BRCA2 Transcript: NM_000059.4
Final call
VUS
BP1 strong
All criteria require review: For research and educational purposes only.
Gene
BRCA2
Transcript
NM_000059.4
Protein
NP_000050.3:p.(Thr200Ala)
gnomAD AF
8.064956399604941e-06 (v4.1)
ClinVar
Uncertain significance
OncoKB
Unknown Oncogenic Effect
Interpretation summary
Generated evidence synthesis
1
VUS: BP1 Strong is met because residue 200 is outside the defined BRCA2 functional domains and SpliceAI maximum delta is 0.073.
2
VUS: no additional benign or pathogenic criterion is met to complete an ENIGMA classification combination.
Final determination: ENIGMA Table 3 does not permit Likely Benign from BP1 Strong alone without additional benign evidence, and with no pathogenic combination met the final call is VUS.
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
Criterion Status Rationale Evidence used
PVS1 N/A Not applicable: c.598A>G is a missense substitution, whereas ENIGMA PVS1 applies to null variants such as nonsense, frameshift, canonical splice-site, initiation-codon, or exon-deletion variants.
cspec vcep_specifications_v1_2_2024_11_18 vcep_appendices_v1_2_2024_11_18 vcep_specifications_table4_v1_2_2024_11_18
PS1 Not met Not met: no previously classified pathogenic variant producing the same p.Thr200Ala substitution was identified for the PS1 comparator requirement.
cspec vcep_supplementarytables_v1_2_2024_11_18 vcep_pmid_31853058_brca2_clinical_history_lr
PS2 N/A Not applicable: the BRCA2 VCEP explicitly says not to use PS2 because de novo occurrences lack calibrated predictive capacity for relatively common BRCA1/2-related cancers.
cspec vcep_specifications_v1_2_2024_11_18
PS3 Not assessed Not assessed: no calibrated damaging protein assay result specific to c.598A>G or p.(Thr200Ala) was found in the governing VCEP sources.
cspec vcep_specifications_v1_2_2024_11_18 vcep_appendices_v1_2_2024_11_18 vcep_specifications_table9_v1_2_2024_11_18 vcep_humu_40_1557_s001 vcep_supplementarytables_v1_2_2024_11_18 PMID:29988080
PS4 Not assessed Not assessed: no variant-specific case-control counts or OR/p-value/95% CI were available to test the VCEP PS4 thresholds (OR ≥4; lower CI >2.0; p ≤0.05).
cspec vcep_supplementarytables_v1_2_2024_11_18 vcep_humu_40_1557_s001
PM1 N/A Not applicable: ENIGMA designates PM1 N/A, and residue 200 lies outside its BRCA2 domains at aa 10-40 and aa 2481-3186.
cspec vcep_specifications_v1_2_2024_11_18 vcep_appendices_v1_2_2024_11_18
PM2 Not assessed Not assessed: the variant is absent from non-cancer gnomAD v2.1/v3.1, but required regional average read depth of at least 25 is unavailable.
cspec gnomad_v2 gnomad_v4 vcep_specifications_v1_2_2024_11_18 vcep_appendices_v1_2_2024_11_18 vcep_supplementarytables_v1_2_2024_11_18 vcep_humu_40_1557_s001
PM3 Not assessed Not assessed: no documented Fanconi Anemia phenotype with a same-gene pathogenic/likely pathogenic co-occurring variant and qualifying phase or homozygous observation was available.
vcep_specifications_v1_2_2024_11_18 cspec
PM4 N/A Not applicable: PM4 is restricted by ENIGMA to in-frame insertion/deletion protein-length changes or stop-loss variants, not the c.598A>G missense substitution.
cspec vcep_specifications_v1_2_2024_11_18
PM5 N/A Not applicable: ENIGMA excludes classic missense PM5 and limits its repurposed form to pathogenic PTC comparisons, whereas c.598A>G is missense.
cspec vcep_specifications_v1_2_2024_11_18 vcep_supplementarytables_v1_2_2024_11_18
PM6 N/A Not applicable: the BRCA2 VCEP explicitly says not to use PM6 because de novo occurrences lack calibrated predictive capacity for relatively common BRCA1/2-related cancers.
cspec vcep_specifications_v1_2_2024_11_18
PP1 Not assessed Not assessed: no quantitative co-segregation LR is available, and the available clinical-history LR is 1.277769323983238 rather than a segregation measure.
cspec vcep_specifications_v1_2_2024_11_18 vcep_pmid_31853058_brca2_clinical_history_lr PMID:31853058
PP2 N/A Not applicable: ENIGMA states missense variants are not a common mechanism of pathogenicity for BRCA1 and BRCA2.
cspec vcep_specifications_v1_2_2024_11_18
PP3 Not met Not met: SpliceAI maximum delta 0.073 is below the ENIGMA PP3 splicing threshold of 0.2 for missense variants.
cspec vcep_specifications_v1_2_2024_11_18 spliceai
PP4 N/A Not applicable: Li et al. clinical-history LR 1.27777 is below the VCEP PP4 supporting threshold, 1.27777 ≥ 2.08? no.
cspec vcep_pmid_31853058_brca2_clinical_history_lr PMID:31853058
PP5 N/A Not applicable: the ENIGMA specification explicitly says PP5 is not to be used for this VCEP framework.
cspec clinvar
BA1 Not met Not met: gnomAD v4.1 grpmax FAF is 6.16e-06, below the ENIGMA BA1 threshold of 0.001, with no non-cancer v2.1/v3.1 observation.
cspec gnomad_v2 gnomad_v4 vcep_specifications_v1_2_2024_11_18 vcep_appendices_v1_2_2024_11_18 vcep_supplementarytables_v1_2_2024_11_18 vcep_humu_40_1557_s001
BS1 Not met Not met: gnomAD v4.1 grpmax FAF is 6.16e-06, below the ENIGMA BS1 Supporting lower boundary of 0.00002.
cspec gnomad_v2 gnomad_v4 vcep_specifications_v1_2_2024_11_18 vcep_appendices_v1_2_2024_11_18 vcep_supplementarytables_v1_2_2024_11_18 vcep_humu_40_1557_s001
BS2 Not assessed Not assessed: gnomAD reports 0 homozygotes, but no qualifying healthy-adult or phenotyped-cohort BS2 observation with VCEP points is available.
cspec gnomad_v4 vcep_specifications_v1_2_2024_11_18 vcep_appendices_v1_2_2024_11_18 vcep_supplementarytables_v1_2_2024_11_18 vcep_humu_40_1557_s001
BS3 Not assessed Not assessed: no calibrated benign protein-function result specific to c.598A>G or p.(Thr200Ala) was found in the governing VCEP sources.
cspec vcep_specifications_v1_2_2024_11_18 vcep_appendices_v1_2_2024_11_18 vcep_specifications_table9_v1_2_2024_11_18 vcep_humu_40_1557_s001 vcep_supplementarytables_v1_2_2024_11_18 PMID:29988080
BS4 Not assessed Not assessed: no variant-specific quantitative non-segregation LR or affected-family-member data are available to compare with the VCEP's supporting threshold of LR ≤0.48:1.
cspec vcep_specifications_v1_2_2024_11_18
BP1 Met Met at strong: residue 200 is outside aa 10-40 and 2481-3186, with SpliceAI maximum delta 0.073 meeting the ≤0.1 threshold.
cspec vcep_specifications_v1_2_2024_11_18 spliceai
BP2 N/A Not applicable: ENIGMA explicitly says BP2 is not used and applies it only in the context of BS2.
vcep_specifications_v1_2_2024_11_18 cspec
BP3 N/A Not applicable: BP3 is restricted to in-frame deletions/insertions, whereas c.598A>G causes the missense substitution p.(Thr200Ala).
cspec vcep_specifications_v1_2_2024_11_18 vcep_appendices_v1_2_2024_11_18
BP4 N/A Not applicable: p.Thr200Ala is a missense variant outside both ENIGMA-defined BRCA2 functional domains covered by the BP4 missense rule.
cspec vcep_specifications_v1_2_2024_11_18 spliceai bayesdel
BP5 Not met Not met: Li et al. clinical-history LR 1.27777 does not satisfy the VCEP BP5 supporting inequality, 1.27777 ≤ 0.48? no.
cspec vcep_pmid_31853058_brca2_clinical_history_lr PMID:31853058
BP6 N/A Not applicable: the ENIGMA specification explicitly says BP6 is not to be used for this VCEP framework.
cspec
BP7 Not assessed Not assessed: BP7_Strong (RNA) covers missense variants outside domains but requires a qualifying mRNA-only assay, which is unavailable for p.Thr200Ala.
cspec vcep_specifications_v1_2_2024_11_18 spliceai
Disclaimer: The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.